This week in Other Barks & Bites: the Federal Circuit announces that Judge Moore will move into the role of Chief Judge for the appellate court this May; the Ninth Circuit revives a case including claims of reverse trademark infringement against Dropbox; HPE, Facebook and Microsoft announce a Low-Carbon Patent Pledge to increase innovator access to patented climate change mitigation technologies; the App Association issues a press release supporting the Department of Justice’s apparent restoration of Obama-era interpretations of FRAND policy for SEP licensing; Ericsson earnings show that the company’s increasing 5G infrastructure sales are helping offset lost patent royalty revenue from Samsung; Judge Roumel orders costs and attorney’s fees against the U.S. government for a late patent validity challenge; and the Supreme Court hears oral arguments in a case that could introduce new limits to the doctrine of patent assignor estoppel.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments
Recent Posts
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments